Alliance Fiber Optic Products, Inc. (Nasdaq:AFOP), an innovative supplier of fiber optic components, subsystems and integrated modules for the optical network equipment market, announced its preliminary sales for the quarter ending March 31, 2014. These results are subject to change as a result of final management review and closing adjustments for the quarter ending on March 31, 2014. Alliance Fiber Optic Products Inc (NASDAQ:AFOP) stock opened today at $16.80 and is currently trading at $16.94. The stock showed a positive weekly performance of -0.47%.
Equities researchers at JPMorgan Chase & Co. initiated coverage on shares of Myriad Genetics (NASDAQ:MYGN) in a research report issued on Monday, StockRatingsNetwork.com reports. The firm set an “underweight” rating and a $25.00 price target on the stock. JPMorgan Chase & Co.’s target price would indicate a potential downside of 28.88% from the company’s current price. Myriad Genetics, Inc. (NASDAQ:MYGN) stock opened at $39.81, in current trading session and currently is at $39.99, by gaining 13.77%.The 52 week range of $20.02-$40.33. Company’s market capitalization is $2.91 billion.
Jan. 27, 2014 Siliconware Precision Industries (ADR) (NASDAQ:SPIL) announced that its consolidated sales revenues for the fourth quarter of 2013 were NT$ 18,844 million, which represented a 1.3% decline in revenues compared to the third quarter of 2013 and a 16.7% growth in revenues compared to the fourth quarter of 2012. SPIL reported a net income of NT$ 2,260 million for the fourth quarter of 2013, compared with a net income of NT$ 2,184 million and a net income of NT$ 1,590 million for the third quarter of 2013 and the fourth quarter of 2012, respectively. Siliconware Precision Industries (ADR) (NASDAQ:SPIL) stock is currently trading at $7.05 .The EPS of the stock is 0.31. Company’s market capitalization is $4.42 billion.
Celgene Corporation and Acceleron Pharma Inc (NASDAQ:XLRN), announced the publication of two papers available online and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells. However, anemias associated with defects in the late-stages of red blood cell formation, known as ineffective erythropoiesis, are resistant to EPO treatment. These studies suggest that sotatercept and ACE-536 may promote and regulate the maturation of late-stage red blood cell precursors and this distinct activity supports the rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including the EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes. Acceleron Pharma Inc (NASDAQ:XLRN) stock opened the session at $38.00, and now is at $39.54. The 52 week range of the XLRN stock remained $16.78-$57.89 and the day range was $37.40-$42.24.